Eupraxia Pharmaceuticals (NASDAQ:EPRX) Raised to Sell at Wall Street Zen

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other research firms also recently commented on EPRX. Oppenheimer restated an “outperform” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, October 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 8th. Wedbush initiated coverage on Eupraxia Pharmaceuticals in a report on Thursday, September 24th. They set an “outperform” rating and a $17.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 15th. Finally, Stifel Nicolaus set a $25.00 price objective on shares of Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.80.

Eupraxia Pharmaceuticals Stock Performance

Eupraxia Pharmaceuticals stock opened at $6.83 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.00 and a quick ratio of 16.00. The stock has a market cap of $444.09 million, a price-to-earnings ratio of -6.70 and a beta of 1.04. The firm has a 50 day simple moving average of $7.59 and a 200-day simple moving average of $7.32. Eupraxia Pharmaceuticals has a 1-year low of $5.25 and a 1-year high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. On average, analysts expect that Eupraxia Pharmaceuticals will post -0.85 EPS for the current year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. Affinity Asset Advisors LLC increased its holdings in shares of Eupraxia Pharmaceuticals by 429.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock valued at $11,504,000 after acquiring an additional 1,289,005 shares during the last quarter. Jupiter Topco LLC acquired a new position in shares of Eupraxia Pharmaceuticals in the second quarter valued at $6,851,000. Seven Fleet Capital Management LP bought a new position in shares of Eupraxia Pharmaceuticals during the 1st quarter worth about $5,137,000. Redmile Group LLC acquired a new position in Eupraxia Pharmaceuticals in the first quarter worth about $5,068,000. Finally, Rubric Capital Management LP acquired a new position in shares of Eupraxia Pharmaceuticals in the 1st quarter worth approximately $5,004,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability.

Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.